• No products in the list


CYP2C19 is a gene that encodes an enzyme belonging to the cytochrome P450 family, which plays a crucial role in the metabolism of various drugs in the body. This enzyme is responsible for the breakdown and elimination of several medications, including antidepressants, proton pump inhibitors, and certain antiepileptic drugs.

Variations in the CYP2C19 gene can significantly affect how individuals respond to medications. These genetic variations can categorize people into different metabolizer types: poor, intermediate, extensive, or ultra-rapid metabolizers.

  • Poor Metabolizers: Have reduced or no enzyme activity. They may not effectively metabolize certain drugs, leading to drug accumulation and increased risk of side effects.
  • Intermediate Metabolizers: Have reduced enzyme activity. They metabolize drugs slower than extensive metabolizers, potentially requiring dosage adjustments.
  • Extensive Metabolizers: Have normal enzyme activity. This group typically responds to standard drug dosages as expected.
  • Ultra-Rapid Metabolizers: Have increased enzyme activity. They metabolize drugs quickly, which may reduce drug efficacy and necessitate higher dosages for therapeutic effect.

Understanding an individual’s CYP2C19 metabolizer status can be critical, especially in treatments requiring precise dosing for efficacy and safety, such as with certain blood thinners like clopidogrel (Plavix).

Genetic testing for CYP2C19 variants can guide healthcare providers in personalizing medication choices and dosages, enhancing treatment effectiveness and reducing the risk of adverse drug reactions. This approach is a key component of pharmacogenomics, which aims to tailor medical treatment to the individual characteristics of each patient.